These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19545786)

  • 21. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
    Sonpavde G; Jian W; Liu H; Wu MF; Shen SS; Lerner SP
    Urol Oncol; 2009; 27(4):391-9. PubMed ID: 18534874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
    Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
    Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
    Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model.
    Yin T; He S; Shen G; Wang Y
    Oncol Res; 2014; 22(3):139-45. PubMed ID: 26168132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
    Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
    BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.
    Olson P; Chu GC; Perry SR; Nolan-Stevaux O; Hanahan D
    Proc Natl Acad Sci U S A; 2011 Dec; 108(49):E1275-84. PubMed ID: 22084065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiogenic blockade and radiotherapy in hepatocellular carcinoma.
    Chi KH; Liao CS; Chang CC; Ko HL; Tsang YW; Yang KC; Mehta MP
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):188-93. PubMed ID: 20133077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.
    Lewin J; Khamly KK; Young RJ; Mitchell C; Hicks RJ; Toner GC; Ngan SY; Chander S; Powell GJ; Herschtal A; Te Marvelde L; Desai J; Choong PF; Stacker SA; Achen MG; Ferris N; Fox S; Slavin J; Thomas DM
    Br J Cancer; 2014 Dec; 111(12):2254-61. PubMed ID: 25321190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
    Zhu AX; Duda DG; Sahani DV; Jain RK
    Cancer J; 2009; 15(4):263-8. PubMed ID: 19672141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound.
    El Kaffas A; Giles A; Czarnota GJ
    Angiogenesis; 2013 Apr; 16(2):443-54. PubMed ID: 23314761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.
    Wang S; Ren W; Liu J; Lahat G; Torres K; Lopez G; Lazar AJ; Hayes-Jordan A; Liu K; Bankson J; Hazle JD; Lev D
    Clin Cancer Res; 2010 May; 16(9):2591-604. PubMed ID: 20406839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
    Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice.
    Bauerschlag DO; Schem C; Tiwari S; Egberts JH; Weigel MT; Kalthoff H; Jonat W; Maass N; Meinhold-Heerlein I
    Anticancer Res; 2010 Sep; 30(9):3355-60. PubMed ID: 20944108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model.
    Chan ES; Patel AR; Hansel DE; Larchian WA; Heston WD
    Urology; 2012 Sep; 80(3):736.e1-5. PubMed ID: 22676953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
    Jiang XL; Zhang Y; Luo CL; Wu XH
    Asian Pac J Cancer Prev; 2012; 13(12):6463-8. PubMed ID: 23464475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
    Yu DS; Wu CL; Ping SY; Huang YL; Shen KH
    J Urol; 2014 Aug; 192(2):559-66. PubMed ID: 24423438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
    Hatipoglu G; Hock SW; Weiss R; Fan Z; Sehm T; Ghoochani A; Buchfelder M; Savaskan NE; Eyüpoglu IY
    Cancer Sci; 2015 Feb; 106(2):160-70. PubMed ID: 25458015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.